Amarin Reports Potential Legacy Effect of Icosapent Ethyl in New REDUCE-IT Analysis
Dublin, Ireland & Bridgewater, N.J. – August 28, 2026 Amarin Corporation announced new post hoc findings from the landmark...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Dublin, Ireland & Bridgewater, N.J. – August 28, 2026 Amarin Corporation announced new post hoc findings from the landmark...
Milan, Italy – August 28, 2026 Zambon announced that the European Commission has granted marketing authorization for Hopledo® (modified-release...
ELK GROVE VILLAGE, Illinois, Aug 28, 2026 Orsini announced that it will serve as a specialty pharmacy partner for...
